Ikena Oncology appoints Francisco Olivera as acting Principal Accounting Officer (Feb 18, 2022)

ImageneBio, Inc.

Appointment made effective February 18, 2022, on an interim basis while a formal CFO search is conducted.
Olivera currently serves as VP of Finance, joined the company in 2019, and has over a decade of biotech experience.
He played a key role in the IPO, Series B financing, and acquisition of Amplify Medicines.
No arrangements or understandings exist with any other person regarding the appointment; no related party transactions reported.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Francisco Olivera

acting Principal Accounting Officer

IMA · ImageneBio, Inc.

Effective: 2022-02-18
Filed: February 24, 2022, 6:59 PM ET

On February 18, 2022, the Board of Directors (the “Board”) of Ikena Oncology, Inc. (the “Company”) unanimously appointed Francisco Olivera as the acting Principal Accounting Officer of the Company.

Departed

Douglas R. Carlson

Other Named Officer

IMA · ImageneBio, Inc.

Effective: 2022-02-18
Successor: Francisco Olivera
Filed: February 24, 2022, 6:59 PM ET

This appointment has been made in connection with the effectiveness of the resignation of Douglas R. Carlson, as previously disclosed on January 28, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Francisco Olivera was appointed as acting Principal Accounting Officer at ImageneBio, Inc..

Action: appointed
Role: acting Principal Accounting Officer

Exact text from the filing

On February 18, 2022, the Board of Directors (the “Board”) of Ikena Oncology, Inc. (the “Company”) unanimously appointed Francisco Olivera as the acting Principal Accounting Officer of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.85

Douglas R. Carlson resigned as other_named_officer at ImageneBio, Inc..

Action: resigned

Exact text from the filing

This appointment has been made in connection with the effectiveness of the resignation of Douglas R. Carlson, as previously disclosed on January 28, 2022

View on SEC.gov

ImageneBio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-052216

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.